Literature DB >> 19603272

Current understanding of risk factors for ovarian cancer.

Thanasak Sueblinvong1, Michael E Carney.   

Abstract

OPINION STATEMENT: Ovarian cancer is the deadliest gynecologic cancer. Unlike many cancers such as breast, cervical and colon cancers, there is no easily clinically identifiable pre-malignant phase of this malignancy making early identification difficult. Similarly, unlike lung, head and neck, and skin cancers, there is not easily identifiable risk factor making prevention short of oophorectomy difficult. Even so, theories as to the causative factors of ovarian cancer continue to evolve making our understanding of the genesis of ovarian cancer more clear. Genetics, parity, environment, hormonal factors, and inflammation all play an important and pivotal role in the development of ovarian cancer. The most current understanding of these elements and their respective contribution to the development of this cancer are presented in this chapter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19603272     DOI: 10.1007/s11864-009-0108-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  121 in total

1.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacob; M J Thun
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies.

Authors:  Anita Koushik; David J Hunter; Donna Spiegelman; Kristin E Anderson; Alan A Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; James R Cerhan; Graham A Colditz; Gary E Fraser; Jo L Freudenheim; Jeanine M Genkinger; R Alexandra Goldbohm; Susan E Hankinson; Karen L Koenig; Susanna C Larsson; Michael Leitzmann; Marjorie L McCullough; Anthony B Miller; Alpa Patel; Thomas E Rohan; Arthur Schatzkin; Ellen Smit; Walter C Willett; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-09       Impact factor: 4.254

3.  Coffee consumption is not associated with ovarian cancer incidence.

Authors:  Susanna C Larsson; Alicja Wolk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-09       Impact factor: 4.254

4.  Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines.

Authors:  S Z Bu; D L Yin; X H Ren; L Z Jiang; Z J Wu; Q R Gao; G Pei
Journal:  Cancer       Date:  1997-05-15       Impact factor: 6.860

5.  Pelvic inflammatory disease and the risk of epithelial ovarian cancer.

Authors:  H A Risch; G R Howe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Jul-Aug       Impact factor: 4.254

Review 6.  Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence.

Authors:  T Riman; I Persson; S Nilsson
Journal:  Clin Endocrinol (Oxf)       Date:  1998-12       Impact factor: 3.478

7.  Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.

Authors:  Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

8.  A quantitative assessment of oral contraceptive use and risk of ovarian cancer.

Authors:  S E Hankinson; G A Colditz; D J Hunter; T L Spencer; B Rosner; M J Stampfer
Journal:  Obstet Gynecol       Date:  1992-10       Impact factor: 7.661

9.  The risk of cancer and the role of parity among women with endometriosis.

Authors:  A Melin; P Sparén; A Bergqvist
Journal:  Hum Reprod       Date:  2007-09-13       Impact factor: 6.918

Review 10.  Hormonal therapy in ovarian cancer.

Authors:  H Zheng; J J Kavanagh; W Hu; Q Liao; S Fu
Journal:  Int J Gynecol Cancer       Date:  2007 Mar-Apr       Impact factor: 3.437

View more
  25 in total

1.  Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.

Authors:  Deirdre P Cronin-Fenton; Liam J Murray; David C Whiteman; Chris Cardwell; Penelope M Webb; Susan J Jordan; Douglas A Corley; Linda Sharp; Jesper Lagergren
Journal:  Eur J Cancer       Date:  2010-04-22       Impact factor: 9.162

2.  A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) Study.

Authors:  Cynthia A Thomson; Tracy E Crane; Austin Miller; David O Garcia; Karen Basen-Engquist; David S Alberts
Journal:  Contemp Clin Trials       Date:  2016-07-06       Impact factor: 2.226

3.  Dynamics of the primate ovarian surface epithelium during the ovulatory menstrual cycle.

Authors:  Jay W Wright; Leigh Jurevic; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

4.  Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population.

Authors:  Piotr Pawlik; Adrianna Mostowska; Margarita Lianeri; Stefan Sajdak; Helena Kędzia; Paweł P Jagodzinski
Journal:  Mol Biol Rep       Date:  2011-12-20       Impact factor: 2.316

5.  Oral contraceptives decrease the prevalence of ovarian cancer in the hen.

Authors:  Lindsey S Treviño; Elizabeth L Buckles; Patricia A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

6.  Three-dimensional modeling of the human fallopian tube fimbriae.

Authors:  Sharon L Eddie; Suzanne M Quartuccio; Jie Zhu; Jessica A Shepherd; Rajul Kothari; J Julie Kim; Teresa K Woodruff; Joanna E Burdette
Journal:  Gynecol Oncol       Date:  2014-12-16       Impact factor: 5.482

7.  Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations.

Authors:  Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Paweł P Jagodzinski
Journal:  Oncol Lett       Date:  2015-12-15       Impact factor: 2.967

8.  Estrogen signaling in microvascular arteries: parturition reduces vasodilation by reducing 17β-estradiol and nNOS.

Authors:  Crista R Royal; Handong Ma; Richard Walker; Richard E White
Journal:  Steroids       Date:  2011-03-31       Impact factor: 2.668

9.  Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population.

Authors:  Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Pawel P Jagodzinski
Journal:  Genet Test Mol Biomarkers       Date:  2013-01-15

10.  Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis.

Authors:  Shanliang Zhong; Lin Chen; Mengmeng Lv; Tengfei Ma; Xiaohui Zhang; Jianhua Zhao
Journal:  Tumour Biol       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.